About Fred Cohen
Fred Cohen is a director at CareDx.
Form D filings name Fred Cohen as a director at Kyverna Therapeutics.
Fred Cohen reports to the SEC as a director or major shareholder of 12 public companies, including Intellia Therapeutics (NTLA), Kyverna Therapeutics (KYTX) and UroGen Pharma (URGN).
Fred Cohen first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Fred Cohen in the role, so the role may have started earlier or lasted longer.
CI
CareDx, Inc.
Director
2014 – 2026 · Public company (CDNA)
II
Intellia Therapeutics, Inc.
Director
2019 – 2026 · Public company (NTLA)
UL
UroGen Pharma Ltd.
Director
2019 – 2024 · Public company (URGN)
PI
Progyny, Inc.
Director
2019 – 2024 · Public company (PGNY)
VI
Veracyte, Inc.
Director
2013 – 2020 · Public company (VCYT)
GI
Genomic Health Inc.
Director
2006 – 2019 · Public company (GHDX)
TI
Tandem Diabetes Care Inc.
Director and 10% owner
2013 – 2018 · Public company (TNDM)
BI
Biocryst Pharmaceuticals Inc.
Director
2013 – 2018 · Public company (BCRX)
RI
Roka BioScience, Inc.
Director
2014 – 2017 · Public company (ROKA)
FI
Five Prime Therapeutics, Inc.
Director
2013 – 2017 · Public company (FPRX)
II
Iqvia Holdings Inc.
Director
2013 · Public company (IQV)
Key Colleagues at Startups
The people Fred Cohen works with at each company, as listed on that company's latest Form D.
Kyverna Therapeutics, Inc. · Form D, Nov 7, 2023
BK
Brian Kotzin
Director
IC
Ian Clark
Director
RJ
Ryan Jones
Chief Financial Officer
KW
Karen Walker
Executive officer
PM
Peter Maag
Executive officer and director
JC
James Chung
Executive officer
DS
Dan Spiegelman
Director
BS
Beth Spiegelman
Director
SL
Steve Liapis
Director
DB
Dominic Borie
Executive officer